Regulatory consideration on preparation and clinical use of COVID-19 convalescent plasma.

Autor: Yılmaz S; Regional Blood Center, University of Health Sciences Gülhane Training and Research Hospital, Ankara, Turkey. Electronic address: soner.yilmaz3@saglik.gov.tr., Ertuğrul Örüç N; Department of Transfusion Services, Health Sciences University Dıskapı Yıldırım Beyazıt, Training and Research Hospital, Ankara, Turkey. Electronic address: nigarertugrul@gmail.com., Özcebe Oİ; Department of Haematology, Hacettepe University School of Medicine, Ankara, Turkey. Electronic address: oozcebe@gmail.com., Azap A; Department of Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey. Electronic address: alpayazap@yahoo.com., Çetin AT; Clinical of Haematology, Memorial Hospital, Ankara, Turkey. Electronic address: tcetin1@gmail.com., Yenicesu İ; EPOS Health Management GmbH, Ankara, Turkey. Electronic address: iyenicesu@gmail.com., Öztürk A; General Directorate of Health Services, Ministry of Health, Ankara, Turkey. Electronic address: abdullah.ozturk@saglik.gov.tr., Gündüz M; General Directorate of Health Services, Ministry of Health, Ankara, Turkey. Electronic address: mehmet.gunduz52@saglik.gov.tr., Tekin A; General Directorate of Health Services, Ministry of Health, Ankara, Turkey. Electronic address: ahmet.tekin42@saglik.gov.tr.
Jazyk: angličtina
Zdroj: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis [Transfus Apher Sci] 2020 Oct; Vol. 59 (5), pp. 102846. Date of Electronic Publication: 2020 Jun 04.
DOI: 10.1016/j.transci.2020.102846
Abstrakt: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), spreading from Wuhan to worldwide has been emerged since December 2019. Although scientists and researchers have been racing to develop specific therapeutic agents or vaccines against SARS-CoV-2 since the identification of the agent, either a drug or a vaccine has not been approved to treat or to prevent COVID-19 up to date. On the base of historical experiences, Convalescent Plasma (CP), a passive antibody therapy, has been evaluated as a hopeful and potential therapeutic option since the beginning of the COVID-19 outbreak. Immune plasma had been used previously for the treatment of H1N1 influenza virus, SARS-CoV-1 and MERS-CoV epidemics successfully. In this scope competent authorities are responsible to set up certain principles and criteria for the collection and clinical use of COVID-19 Convalescent Plasma (CCP). This document has been prepared to aid both for the convalescent plasma suppliers and the clinicians. The first part encompasses the supply of CCP and the second part lead the clinical use of CCP for the treatment of patients with severe COVID-19 infection. Turkish Ministry of Health developed a guide on collection and clinical use of CCP and created a web-based monitoring system to follow-up the patients treated with convalescent plasma in universal. This follow-up process is thought to be crucial for the creation and development of current and future treatment modalities. This guide would be a pathfinder for clinicians and/or institutions those eager to conduct CCP treatment more effectively.
(Copyright © 2020 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: